HCMV16

Antibody Name: HCMV16 (SGIIA|kIII)
References: Hamilton, A.A., Manuel, D.M., Grundy, J.E., Turner, A.J., King, S.I., Adair, J.R., White, P., Carr, F.J. and Harris, W.J. "A humanized antibody against Human Cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections" J. Infect. Diseases (1997) 176:59-68.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: gH envelope glycoprotein of human cytomegalovirus (HCMV).
Laboratory: Scotgen Biopharmaceuticals Inc., UK; University of Aberdeen, UK; Royal Free Hospital School of Medicine, UK
Design: Used NEWM | REI FRs, but also tried best-fit strategy with EU.
Frameworks: VH NEWM or EU/FR4 NEWM | VL REI
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: Best version based on NEWM
VH V24A S27Y S30T KNQFS75-79ASTAY Y91F
VL none
Binding: Both NEWM- and EU-based mAbs showed "near equivalent" neutralisation of CMV strain AD169 to the chimaeric mAb. In immunoassay, NEWM showed ~2-fold better binding to gH than EU.
Expression: NS0 or YB2/0
Comment: Their results question the best-fit approach. Lonza Biologics, UK are developing cell lines for large-scale production of the mAb using the GS gene amplification system (Bebbington et al (1992) Biotech. 10:169-175).
Clinical Indication: Passive immunisation either alone or in combination with antiviral agents may play an important role in the treatment or prevention (or both) of HCMV infections in immunocompromised patients.

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.